New study tracks safety of growth hormone drug in kids
NCT ID NCT06587035
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This study is watching for side effects in 50 children in India who are prescribed somatrogon, a long-acting growth hormone injection for growth hormone deficiency. The goal is to see how safe the drug is during routine care over 3 years. Participants do not have to visit the clinic regularly; follow-ups can be by phone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- somatrogon (a long-acting growth hormone injection)
- What this could lead to
- If this study shows somatrogon is safe, it could support its continued use for children with growth hormone deficiency in India.
- What could go wrong
- This is an observational safety study, not a test of effectiveness. It is small (50 participants) and only monitors side effects, so it cannot prove the drug works better than other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DWARFISM, PITUITARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Apollo Children's Hospital
RECRUITINGChennai, Tamil Nadu, 600006, India
-
Apollo Speciality Hospital
RECRUITINGMadurai, Tamil Nadu, 625020, India
-
G Kuppuswamy Naidu Memorial Hospital
RECRUITINGCoimbatore, Tamil Nadu, 641037, India
-
Shivajoyti Clinic
RECRUITINGBengaluru, Karnataka, 560008, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.